Merck KGaA is buying Natrix Separations Inc, the Canadian supplier of hydrogel membrane products for single-use chromatography.

“The Natrix technology platform, and the development options and capabilities that this brings for single-use and rapid cycling chromatography, will allow us to accelerate our offering in mAb and vaccine manufacturing,” said Udit Batra, member of the Merck executive board and CEO, Life Science. “This acquisition creates tremendous opportunity to drive growth and advancement in next-generation processing — an area of increasing importance to our customers.”

“Joining Merck gives us the opportunity to collaborate with some of the best minds in the industry, allowing us to further the great work done by our scientists,” said John Chickosky, CEO of Natrix Separations. “I am truly excited to become part of a larger effort and see the benefits of this combination in the advances we will make for our customers and the global scientific community.”